Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

作者：黄莺俗话说人红是非多。在新冠疫情期间，凭借mRNA疫苗大获成功的Moderna公司，从年营收只有几千万美元的公司，一举跨入年营收200亿美元的公司行列。而这为其也带来了越来越多的专利纠纷。2021年，Moderna与美国国立卫生研究院的mRNA ...

We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...

智通财经APP获悉，周三，美国西北大学 (Northwestern University)在特拉华州联邦法院对Moderna (MRNA.US)提起了一项新的专利诉讼，指控该公司滥用该校的创新成果来开发其重磅的新冠疫苗Spikevax。

Moderna ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $54.82 which represents a decrease of $-2.64 or -4.59% from the prior close of $57.46. The stock opened at $57.08 and touched a ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

格隆汇10月17日｜美国西北大学在特拉华州联邦法院对Moderna提起了一项新的专利诉讼。该诉讼称，Moderna在新冠疫苗Spikevax中未经许可使用西北大学开发的脂质纳米颗粒(LNP)技术，将脆弱的mRNA运输到人体内。Moderna的一位发言 ...

Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK ...

斯微生物成立于2016年，是中国率先开展mRNA药物研发和mRNA肿瘤精准疫苗人体临床试验的创新型企业之一。不过直到2020年，由于新冠疫情的暴发，mRNA疫苗才成功破圈进入公众视野，斯微生物也逐渐成为众多明星资本加码的对象。

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Moderna (NasdaqGS:MRNA) with a Market Perform ...

在充满挑战的市场环境中，Moderna Inc. (MRNA)股价已触及52周低点，跌至57.71美元。这家以mRNA疫苗闻名的生物技术公司在过去一年经历了动荡，其股价反映出显著下滑。过去一年，Moderna股价下跌了42.71%，表明投资者情绪看空 ...